{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:23Z","timestamp":1793520023095,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40265-023-01886-5","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T14:53:11Z","timestamp":1684162391000},"page":"739-745","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Cipaglucosidase Alfa: First Approval"],"prefix":"10.1007","volume":"83","author":[{"given":"Hannah A.","family":"Blair","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"1886_CR1","unstructured":"National Organization for Rare Disorders (NORD). Pompe disease. 2021. https:\/\/rarediseases.org\/rare-diseases\/pompe-disease\/. Accessed 1 May 2023."},{"key":"1886_CR2","unstructured":"Amicus Therapeutics Europe Limited. Pombiliti (cipaglucosidase alfa) 105 mg powder for concentrate for solution for infusion: EU summary of product characteristics. 2023. https:\/\/ec.europa.eu\/health\/documents\/community-register\/2023\/20230320158375\/anx_158375_en.pdf. Accessed 1 May 2023."},{"issue":"12","key":"1886_CR3","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S1474-4422(21)00331-8","volume":"20","author":"B Schoser","year":"2021","unstructured":"Schoser B, Roberts M, Byrne BJ, et al. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial. Lancet Neurol. 2021;20(12):1027\u201337.","journal-title":"Lancet Neurol"},{"issue":"9","key":"1886_CR4","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.3390\/biom10091339","volume":"10","author":"NK Meena","year":"2020","unstructured":"Meena NK, Raben N. Pompe disease: new developments in an old lysosomal storage disorder. Biomolecules. 2020;10(9):1339.","journal-title":"Biomolecules"},{"key":"1886_CR5","unstructured":"Amicus Therapeutics. Amicus Therapeutics announces European Commission approval for Pombiliti\u2122 in patients with late-onset Pompe disease [media release]. 27 Mar 2023. https:\/\/ir.amicusrx.com\/news-releases\/news-release-details\/amicus-therapeutics-announces-european-commission-approval-1."},{"key":"1886_CR6","unstructured":"Amicus Therapeutics. Amicus Therapeutics strengthens biologics business strategy [media release]. 20 Nov 2013. http:\/\/www.amicusrx.com."},{"key":"1886_CR7","unstructured":"WuXi Biologics. WuXi Biologics and Amicus sign exclusive manufacturing partnership [media release]. 11 Feb 2019. http:\/\/www.wuxibiologics.com."},{"key":"1886_CR8","unstructured":"Amicus Therapeutics. Amicus Therapeutics issued two U.S. patents for Pompe enzyme ATB200 [media release]. 20 Mar 2019. http:\/\/www.amicusrx.com."},{"issue":"2","key":"1886_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ymgme.2022.107042","volume":"138","author":"B Byrne","year":"2023","unstructured":"Byrne B, Schoser B, Kishnani P, et al. Long-term follow-up of cipaglucosidase alfa\/miglustat in ambulatory patients with Pompe disease: an open-label phase I\/II study (ATB200-02) [abstract no. 59 plus poster]. Mol Genet Metab. 2023;138(2):21\u20132.","journal-title":"Mol Genet Metab"},{"key":"1886_CR10","doi-asserted-by":"crossref","unstructured":"Johnson FK, Kang J, Mondick J, et al. Mechanism of action, pharmacokinetic profiles, and pharmacokinetic\/pharmacodynamic relationships differ between cipaglucosidase alfa\/miglustat and alglucosidase alfa in late-onset Pompe disease [abstract no. 166 plus poster]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2022.","DOI":"10.1016\/j.ymgme.2021.11.158"},{"issue":"2","key":"1886_CR11","doi-asserted-by":"publisher","first-page":"S27","DOI":"10.1016\/j.ymgme.2021.11.054","volume":"135","author":"B Byrne","year":"2022","unstructured":"Byrne B, Bratkovic D, D\u00edaz-Manera J, et al. Cipaglucosidase alfa\/miglustat versus alglucosidase alfa\/placebo in late-onset Pompe disease (LOPD): PROPEL study subgroup analyses [abstract no. 39 plus poster]. Mol Genet Metab. 2022;135(2):S27\u20138.","journal-title":"Mol Genet Metab"},{"issue":"7 Suppl","key":"1886_CR12","doi-asserted-by":"publisher","first-page":"S553","DOI":"10.1016\/j.jval.2022.04.1412","volume":"25","author":"S Raza","year":"2022","unstructured":"Raza S, Keyzor I, Shohet S, et al. Association of walking distance with quality of life and other patient-reported outcomes in Pompe disease [abstract no. PCR67]. Value Health. 2022;25(7 Suppl):S553.","journal-title":"Value Health."},{"key":"1886_CR13","unstructured":"Schoser B, Bratkovic D, Byrne B, et al. Long-term efficacy and safety of cipaglucosidase alfa\/miglustat in ambulatory patients with Pompe disease: a phase III open-label extension study (ATB200-07) [poster no. LB-59 plus oral presentation]. In: 19th Annual WORLDSymposiumTM. 2023."},{"key":"1886_CR14","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.ymgme.2018.12.084","volume":"126","author":"PR Clemens","year":"2019","unstructured":"Clemens PR, Mozaffar T, Schoser B, et al. Safety and efficacy of advanced and targeted acid \u03b1-glucosidase (AT-GAA) (ATB200\/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial [abstract no. 68]. Mol Genet Metab. 2019;126:S40\u20131.","journal-title":"Mol Genet Metab"},{"key":"1886_CR15","unstructured":"Benjamin E, Schoser B, Kishnani P, et al. Immunogenicity of cipaglucosidase alfa\/miglustat versus alglucosidase alfa\/placebo in late-onset Pompe disease: a phase III, randomized study (PROPEL) [abstract no. 185 plus poster]. In: American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting. 2022."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01886-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01886-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:14:18Z","timestamp":1744715658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01886-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["1886"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01886-5","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"15 May 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Hannah Blair is a salaried employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}